November 09, 2016
4 min watch
Save

VIDEO: Ibalizumab reduces viral load in patients with MDR HIV

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW ORLEANS — Jacob Lalezari, MD, medical director for Quest Clinical Research, discusses results from a phase 3 trial of ibalizumab — a long-acting humanized monoclonal antibody administered intravenously every 2 weeks — which significantly reduced viral load in treatment-experienced patients with multidrug-resistant HIV. Among the study participants, 83% achieved at least a 0.5 log10 decrease in HIV-1 RNA by day 14 of therapy, and 60% achieved at least a 1 log10 decrease in viral load.

“[There is] very significant antiviral activity with ibalizumab in this most difficult, most vulnerable population,” Lalezari says. “Not enough to potentially stop the virus as a single agent in somebody who’s failing, but definitely an important new tool with which to cobble together a regimen — potentially the last regimen — for a patient to both get their virus under control and then prevent the spread of that virus to somebody else.”

Disclosure: The study was supported by TaiMed Biologics.